Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, June 1, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Christopher Raymond Maintained (BIIB) at Buy with Increased Target to $360 on, Jun 1st, 2023
Christopher Raymond of Piper Sandler, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $346 to $360 on, Jun 1st, 2023.
Christopher has made no other calls on BIIB in the last 4 months.
There are 15 other peers that have a rating on BIIB. Out of the 15 peers that are also analyzing BIIB, 4 agree with Christopher's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Laura Chico of "Wedbush" Reiterated at Hold and Held Target at $263 on, Tuesday, May 23rd, 2023
- Geoff Meacham of "B of A Securities" Maintained at Hold with Increased Target to $320 on, Thursday, May 4th, 2023
- Steve Chesney of "Atlantic Equities" Maintained at Hold with Decreased Target to $282 on, Wednesday, April 26th, 2023
- Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $302 on, Wednesday, April 26th, 2023
These are the ratings of the 11 analyists that currently disagree with Christopher
- Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $350 on, Thursday, May 11th, 2023
- Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Increased Target to $350 on, Monday, May 1st, 2023
- Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $325 on, Wednesday, April 26th, 2023
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $330 on, Wednesday, April 26th, 2023
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $371 on, Wednesday, April 26th, 2023
- Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $321 on, Wednesday, April 26th, 2023
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $325 on, Wednesday, April 26th, 2023
- Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $340 on, Wednesday, April 26th, 2023
- Matthew Korn of "Morgan Stanley" Maintained at Buy with Decreased Target to $349 on, Wednesday, April 12th, 2023
- Phil Nadeau of "Cowen & Co." Maintained at Buy with Increased Target to $315 on, Thursday, February 16th, 2023
- Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $340 on, Thursday, February 16th, 2023
